NICE publishes new myeloma guidance
February 10, 2016Medical Communications, Research and Development Farydak, Novartis, multiple myeloma
NICE has set out best practice for the diagnosis, monitoring and treatment of myeloma, in new guidelines published today. Myeloma …
Novartis says CDF proposals place “unreasonable” risk on pharma
February 10, 2016Medical Communications, Research and Development, Sales and Marketing Cancer Drugs Fund, NHS England, NICE, Novartis
Novartis has criticised some of the proposed changes to the way in which the UK Cancer Drugs Fund (CDF) is …
Heptares announces positive early-stage dementia trial results
February 10, 2016Research and Development Alzheimer's, Alzheimers, Heptares, dementia, schizophrenia
Heptares has announced positive findings from its Phase 1b clinical study with its investigational drug HTL9936 as a treatment for …
FDA advisory committee recommends approval of Remicade biosimilar
February 10, 2016Research and Development, Sales and Marketing FDA, Pfizer, Remicade, biosimilar, celltrion
An FDA advisory panel yesterday voted overwhelmingly in favour of approving CT-P13- Celltrion’s biosimilar version of Johnson&Johnson’s blockbuster arthritis drug …
New breast cancer initiative brings together pharma and Europe’s top researchers
February 9, 2016Medical Communications, Research and Development Pfizer, breast cancer
The UK charity Breast Cancer Now (BCN) has announced a new initiative seeking to bring together Europe’s top researchers and …
Pfizer names leadership team post-Allergan merger
February 9, 2016Manufacturing and Production, Sales and Marketing Allergan, Pfizer
Pfizer has announced the executive leadership team for the combined Pfizer and Allergan business once the $160 billiion merger deal …
INTERVIEW: Tackling the Zika threat
February 9, 2016Manufacturing and Production, Medical Communications Zika, vaccines
The Zika outbreak which started in Brazil and spread rapidly to other south American countries and beyond has taken the …
FDA set to approve Remicade biosimilar
February 9, 2016Manufacturing and Production, Research and Development, Sales and Marketing Remicade, biosimilars, remsima
An FDA committee has had some positive words for Celltrion’s biosimilar candidate to Janssen/MSD’s Remicade (infliximab), concluding that the copycat biologic …
NICE changes mind on Amgen’s cholesterol drug
February 8, 2016Manufacturing and Production, Sales and Marketing Amgen, NICE, Repatha
NICE has changed its mind on Amgen’s cholesterol-busting drug Repatha (evolocumab), and decided to recommend approval of the treatment in …
Merck partners with Ugandan Health Ministry to tackle cancer awareness
February 8, 2016Manufacturing and Production, Medical Communications Africa, Cancer, Merck
Germany’s Merck celebrated World Cancer Day by collaborating with the Uganda Ministry of Health to raise awareness about early detection …
NICE rejects cholesterol drug Praluent in draft guidance
February 8, 2016Research and Development, Sales and Marketing NICE, Regeneron, Sanofi, cholesterol
NICE has published draft guidance not recommending Sanofi/Regeneron’s Praluent (alirocumab) as an option for people with high cholesterol (primary hypercholesterolaemia …
UK Health Secretary sets out £4.2 billion ‘digital NHS’ vision
February 8, 2016Medical Communications, Sales and Marketing Jeremy Hunt, NHS
UK Health Secretary Jeremy Hunt has announced a £4.2 billion investment in the National Health Service (NHS) which will help …
FDA to decide on Shire blockbuster hopeful
February 8, 2016Manufacturing and Production, Research and Development, Sales and Marketing Shire, dry eye disease, lifitegrast
The FDA has accepted Shire’s new drug application (NDA) for its dry eye disease drug lifitegrast, putting the treatment on …
UK lung cancer patients get early access to breakthrough BMS drug
February 5, 2016Research and Development, Sales and Marketing Bristol-Myers Squibb, MHRA, NICE, eams, opdivo
UK lung cancer patients are to get access to Bristol Myers-Squibb’s Opdivo (nivolumab) through the Early Access to Medicines Scheme …
Big pharma answers tough questions at US drug pricing hearing
February 5, 2016Medical Communications Drug pricing, FDA, Martin Shkreli, Senate, Turing Pharmaceuticals, US, Valeant, congress
Pharmaceutical industry executives came under intense scrutiny at a Congressional hearing in the US as the debate over the spiralling …
Parliamentary committee says CDF must make better use of taxpayer money
February 5, 2016Medical Communications Cancer Drugs Fund, Public Accounts Committee
The Cancer Drugs Fund, set up to improve patients’ access to cancer drugs, has not been managed effectively, a UK …
Lundbeck gets go-ahead for US and EU licence expansions
February 4, 2016Medical Communications, Sales and Marketing Abilify, EMA, FDA, Lundbeck, Otsuka, Takeda, aripiprazole, brintellix, vortioxetine
Lundbeck has earned two recommendations from regulatory committees of the FDA and the EMA, which both recommended the company’s drugs …
Investigation questions Xarelto trial data accuracy
February 4, 2016Medical Communications BMJ, Bayer, INR, Johnson & Johnson, New England Journal of Medicine, Rocket-AF, Xarelto, blood clotting, rivaroxaban
The ROCKET-AF trial, the pivotal trial of the top-selling anti-clotting drug Xarelto, could have been undermined by unreliable results from …
Human Longevity makes three oncology appointments
February 4, 2016Research and Development human longevity
Human Longevity, the genomics-based, technology company, has appointed ‘several key people’ for its oncology genomics program.Dr Kenneth Bloom will join …
AZ warns of patent losses as revenues fall
February 4, 2016Medical Communications, Sales and Marketing AstraZeneca, Crestor, Zurampic
AstraZeneca announced full-year revenues down 7% to $24.7 billion, and Q4 sales down 5% to $6.4 billion, as the London-based …
Latest content
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEO
Tridem begins phase Ib trial of Parkinson’s disease vaccine
